Self-expanding metallic stent as a bridge to surgery versus emergency resection for obstructing colorectal cancer: an overlap-weighted single-centre cohort study of definitive operative outcome

When a person develops colorectal cancer, the most urgent danger is not always the tumor itself, but the blockage it can cause. Imagine a highway suddenly closed by a landslide; traffic backs up, pressure builds, and the situation becomes critical within hours. In the human body, this blockage is a large-bowel obstruction, a medical emergency that often forces surgeons to operate immediately. The standard approach has long been to remove the tumor right away, but operating on a swollen, urgent bowel is difficult. It often requires a large incision and, more frequently than planned surgery, leaves the patient with a stoma—a temporary or permanent opening in the abdomen to collect waste. This is a life-altering change that many patients hope to avoid if possible.

For years, doctors have debated a different path: placing a small, expandable metal mesh tube inside the blocked colon to clear the blockage first. This device, called a self-expanding metallic stent, acts like a temporary scaffold, allowing the bowel to decompress and the patient to recover. Once the patient is stable, surgeons can perform the tumor removal later, in a calm, planned setting. This "bridge to surgery" approach promises the chance for a less invasive operation and a better chance of avoiding a stoma. However, the medical community has been cautious. While the stent clears the path, it carries its own risks, such as the possibility of puncturing the bowel wall. The question remains: does this two-step strategy actually lead to a better overall outcome for the patient, or does the risk of the first step outweigh the benefits of the second?

Researchers at Zhuhai People's Hospital in China set out to answer this by looking back at the records of sixty patients who faced this exact dilemma between 2020 and 2026. They compared two groups: those who received the stent first and then had their tumor removed later, and those who went straight to emergency surgery. To make a fair comparison, the team used a statistical method that balanced the groups based on factors like age, sex, and prior health, focusing specifically on patients for whom either treatment would have been a realistic choice. Their goal was not just to count individual successes or failures, but to define a single, clear picture of a "good" operation. They defined a favorable outcome as a surgery that was performed using a minimally invasive laparoscopic technique, did not require a stoma, and resulted in no significant complications that required extra medical treatment.

The results showed a distinct advantage for the group that received the stent first. Among the thirty-six patients who took the stent route, twenty-one achieved this favorable outcome, which is roughly 58 percent. In contrast, only eight of the twenty-four patients who went straight to emergency surgery, or about 33 percent, reached the same goal. When the researchers adjusted for the differences between the patients, the data suggested that choosing the stent first increased the chance of a favorable operation by nearly 28 percentage points. The most significant benefit was in avoiding a stoma; the stent group was much more likely to have their bowel continuity restored without an external bag. They were also more likely to have the surgery performed through small keyhole incisions rather than a large open cut.

However, the study also highlighted the risks involved in the stent strategy. Two patients in the stent group experienced a perforation, a hole in the bowel caused by the device, which is a serious complication. Additionally, three patients in that group required surgery because the stent failed to clear the blockage. Despite these setbacks, the overall rate of significant complications was not higher in the stent group compared to the emergency surgery group. The patients who received the stent also spent less time in the hospital after their final surgery, with a median stay of nine days compared to twelve days for those who had emergency surgery.

The researchers were careful to note that their findings come with a degree of uncertainty due to the relatively small number of patients involved. When they added more details to their analysis, such as whether patients smoked or had a history of other cancers, the estimated benefit of the stent strategy became smaller and less certain, though it still pointed in the same positive direction. The study did not track long-term cancer survival or recurrence rates, so it cannot say whether one approach is better for curing the disease in the long run. What it does show is that for patients who successfully undergo tumor removal, starting with a stent appears to create better conditions for the final surgery, making it more likely to be less invasive and less likely to leave a patient with a stoma.

Ultimately, this work suggests that the stent-first approach is a viable option that can improve the surgical experience for many patients with obstructing colorectal cancer. It offers a way to turn a chaotic emergency into a planned procedure, potentially sparing patients from the physical and emotional burden of a stoma. Yet, the decision is not without risk, and the benefits must be weighed against the small chance of the stent causing a perforation. The authors conclude that this strategy should be part of a shared conversation between doctor and patient, helping them choose the path that best fits the individual's situation, rather than a rule that applies to everyone. The study serves as a reminder that in medicine, the goal is not just to remove a tumor, but to guide the patient through the entire process with the best possible outcome in mind.